Extracellular nucleotides are potent signaling molecules mediating cell-specific biological functions, mostly within the processes of tissue damage and repair and flogosis. We previously demonstrated that adenosine 5′-triphosphate (ATP) inhibits the proliferation of human bone marrow-derived mesenchymal stem cells (BM-hMSCs), while stimulating, in vitro and in vivo, their migration. Here, we investigated the effects of ATP on BM-hMSC differentiation capacity. Molecular analysis showed that ATP treatment modulated the expression of several genes governing adipogenic and osteoblastic (ie, WNT-pathway-related genes) differentiation of MSCs. Functional studies demonstrated that ATP, under specific culture conditions, stimulated adipogenesis by significantly increasing the lipid accumulation and the expression levels of the adipogenic master gene PPARγ (peroxisome proliferator-activated receptor-gamma). In addition, ATP stimulated osteogenic differentiation by promoting mineralization and expression of the osteoblast-related gene RUNX2 (runt-related transcription factor 2). Furthermore, we demonstrated that ATP stimulated adipogenesis via its triphosphate form, while osteogenic differentiation was induced by the nucleoside adenosine, resulting from ATP degradation induced by CD39 and CD73 ectonucleotidases expressed on the MSC membrane. The pharmacological profile of P2 purinergic receptors (P2Rs) suggests that adipogenic differentiation is mainly mediated by the engagement of P2Y1 and P2Y4 receptors, while stimulation of the P1R adenosine-specific subtype A2B is involved in adenosine-induced osteogenic differentiation. Thus, we provide new insights into molecular regulation of MSC differentiation.
HorwitzEM, Le BlancK, DominiciM, MuellerI, Slaper-CortenbachI, MariniFC, DeansRJ, KrauseDS, KeatingA. 2005. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 7:393–395.
Le BlancK. 2003. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy, 5:485–489.
6.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE, DazziF. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
7.
FibbeWE, NautaAJ, RoelofsH. 2007. Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci, 1106:272–278.
8.
UccelliA, MorettaL, PistoiaV. 2006. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol, 36:2566–2573.
9.
EliopoulosN, StaggJ, LejeuneL, PommeyS, GalipeauJ. 2005. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106:4057–4065.
10.
PonceletAJ, VercruysseJ, SaliezA, GianelloP. 2007. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation, 83:783–790.
11.
IsakovaIA, DufourJ, LanclosC, BruhnJ, PhinneyDG. 2010. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp Hematol, 38:957–967.e1.
CaplanAI. 2007. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213:341–347.
14.
LemoliRM, BertoliniF, CanceddaR, De LucaM, Del SantoA, FerrariG, FerrariS, MartinoG, MavilioF, TuraS. 2005. Stem cell plasticity: time for a reappraisal?Haematologica, 90:360–381.
15.
AluigiM, FogliM, CurtiA, IsidoriA, GruppioniE, ChiodoniC, ColomboMP, VersuraP, D'Errico-GrigioniAet al.2006. Nucleofection is an efficient nonviral transfection technique for human bone marrow–derived mesenchymal stem cells. Stem Cells, 24:454–461.
RytenM, DunnPM, NearyJT, BurnstockG. 2002. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J Cell Biol, 158:345–355.
18.
SakK, BoeynaemsJM, EverausH. 2003. Involvement of P2Y receptors in the differentiation of haematopoietic cells. J Leukoc Biol, 73:442–447.
19.
BurnstockG. 2006. Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci, 27:166–176.
20.
GachetC. 2008. P2 receptors, platelet function and pharmacological implications. Thromb Haemost, 99:466–472.
21.
BoursMJ, SwennenEL, Di VirgilioF, CronsteinBN, DagneliePC. 2006. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther, 112:358–404.
22.
Di VirgilioF. 2012. Purines, purinergic receptors, and cancer. Cancer Res, 72:5441–5447.
23.
BurnstockG, KnightGE, GreigAV. 2012. Purinergic signaling in healthy and diseased skin. J Invest Dermatol, 132:526–546.
24.
RalevicV, BurnstockG. 1998. Receptors for purines and pyrimidines. Pharmacol Rev, 50:413–492.
25.
AbbracchioMP, BurnstockG, BoeynaemsJM, BarnardEA, BoyerJL, KennedyC, KnightGE, FumagalliM, GachetC, JacobsonKA, WeismanGA. 2006. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev, 58:281–341.
26.
BurnstockG. 2007. Purine and pyrimidine receptors. Cell Mol Life Sci, 64:1471–1483.
27.
ZimmermannH. 2000. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol, 362:299–309.
28.
YegutkinGG. 2008. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta, 1783:673–694.
29.
ShryockJC, BelardinelliL. 1997. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol, 79:2–10.
30.
FredholmBB. 2007. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ, 14:1315–1323.
31.
FredholmBB. 2010. Adenosine receptors as drug targets. Exp Cell Res, 316:1284–1288.
32.
FredholmBB, IJzermanAP, JacobsonKA, KlotzKN, LindenJ. 2011. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev, 63:1–34.
33.
FerrariD, GulinelliS, SalvestriniV, LucchettiG, ZiniR, ManfrediniR, CaioneL, PiacibelloW, CiciarelloMet al.2011. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp Hematol, 39:360–374.
34.
LemoliRM, FerrariD, FogliM, RossiL, PizziraniC, ForchapS, ChiozziP, VaselliD, BertoliniFet al.2004. Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood, 104:1662–1670.
35.
RossiL, ManfrediniR, BertoliniF, FerrariD, FogliM, ZiniR, SalatiS, SalvestriniV, GulinelliSet al.2007. The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood, 109:533–542.
36.
SalvestriniV, ZiniR, RossiL, GulinelliS, ManfrediniR, BianchiE, PiacibelloW, CaioneL, MigliardiGet al.2012. Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood, 119:217–226.
37.
LivakKJ, SchmittgenTD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25:402–408.
38.
OttoF, ThornellAP, CromptonT, DenzelA, GilmourKC, RosewellIR, StampGW, BeddingtonRS, MundlosSet al.1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89:765–771.
KimHJ, MinashimaT, McCarthyEF, WinklesJA, KirschT. 2010. Progressive ankylosis protein (ANK) in osteoblasts and osteoclasts controls bone formation and bone remodeling. J Bone Miner Res, 25:1771–1783.
41.
KomoriT. 2010. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res, 339:189–195.
42.
LaveryK, SwainP, FalbD, Alaoui-IsmailiMH. 2008. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem, 283:20948–20958.
43.
SiW, KangQ, LuuHH, ParkJK, LuoQ, SongWX, JiangW, LuoX, LiXet al.2006. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol, 26:2955–2964.
44.
SchedlichLJ, MuthukaruppanA, O'HanMK, BaxterRC. 2007. Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts. Mol Endocrinol, 21:2378–2390.
45.
GiustinaA, MazziottiG, CanalisE. 2008. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev, 29:535–559.
46.
FarmerSR. 2006. Transcriptional control of adipocyte formation. Cell Metab, 4:263–273.
47.
ChangBH, LiL, PaulA, TaniguchiS, NannegariV, HeirdWC, ChanL. 2006. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol, 26:1063–1076.
48.
ZhangJ, XiaWL, AhmadF. 1995. Regulation of pyruvate carboxylase in 3T3-L1 cells. Biochem J, 306:205–210.
49.
EastmanSW, YassaeeM, BieniaszPD. 2009. A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J Cell Biol, 184:881–894.
50.
JacquesC, ReckliesAD, LevyA, BerenbaumF. 2007. HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions. Osteoarthritis Cartilage, 15:138–146.
CombsTP, WagnerJA, BergerJ, DoebberT, WangWJ, ZhangBB, TanenM, BergAH, O'RahillySet al.2002. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology, 143:998–1007.
53.
ParkSK, OhSY, LeeMY, YoonS, KimKS, KimJW. 2004. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes, 53:2757–2766.
54.
WellnerM, HerseF, JankeJ, GorzelniakK, EngeliS, BechartD, LasalleP, LuftFC, SharmaAM. 2003. Endothelial cell specific molecule-1—a newly identified protein in adipocytes. Horm Metab Res, 35:217–221.
55.
GonçalvesCA, LeiteMC, GuerraMC. 2010. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol, 2010:790431.
BolandGM, PerkinsG, HallDJ, TuanRS. 2004. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem, 93:1210–1230.
58.
RajalinAM, AarnisaloP. 2011. Cross-talk between NR4A orphan nuclear receptors and β-catenin signaling pathway in osteoblasts. Arch Biochem Biophys, 509:44–51.
59.
ChanTF, CouchourelD, AbedE, DelalandreA, DuvalN, LajeunesseD. 2011. Elevated Dickkopf-2 levels contribute to the abnormal phenotype of human osteoarthritic osteoblasts. J Bone Miner Res, 26:1399–1410.
60.
YaoW, ChengZ, ShahnazariM, DaiW, JohnsonML, LaneNE. 2010. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res, 25:190–199.
61.
ChoHY, ChoiHJ, SunHJet al.2010. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone, 47:263–271.
62.
MurraySS, GrisantiMS, BentleyGV, KahnAJ, UristMR, MurrayEJ. 1997. The calpain-calpastatin system and cellular proliferation and differentiation in rodent osteoblastic cells. Exp Cell Res, 233:297–309.
63.
OuyangX, FujimotoM, NakagawaR, SeradaS, TanakaT, NomuraS, KawaseI, KishimotoT, NakaT. 2006. SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. J Cell Physiol, 207:428–436.
64.
YoshikoY, MaedaN, AubinJE. 2003. Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. Endocrinology, 144:4134–4143.
65.
CornishJ, GillespieMT, CallonKE, HorwoodNJ, MoseleyJM, ReidIR. 2003. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology, 144:1194–1201.
66.
GordonJA, HassanMQ, KossM, MontecinoM, SelleriL, van WijnenAJ, SteinJL, SteinGS, LianJB. 2011. Epigenetic regulation of early osteogenesis and mineralized tissue formation by a HOXA10-PBX1-associated complex. Cells Tissues Organs, 194:146–150.
67.
FortunatiD, ReppeS, FjeldheimAK, NielsenM, GautvikVT, GautvikKM. 2010. Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. Matrix Biol, 29:594–601.
68.
BilliardJ, MoranRA, WhitleyMZ, Chatterjee-KishoreM, GillisK, BrownEL, KommBS, BodinePV. 2003. Transcriptional profiling of human osteoblast differentiation. J Cell Biochem, 89:389–400.
NistalaH, Lee-ArteagaS, SmaldoneS, SicilianoG, CartaL, OnoRN, SengleG, Arteaga-SolisE, LevasseurRet al.2010. Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol, 190:1107–1121.
71.
SpiegelmanBM, HuE, KimJB, BrunR. 1997. PPAR gamma and the control of adipogenesis. Biochimie, 79:111–112.
72.
SattlerC, SteinsdoerferM, OffersM, FischerE, SchierlR, HeselerK, DäubenerW, SeisslerJ. 2011. Inhibition of T cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant, 20:1221–1230.
73.
Saldanha-AraujoF, FerreiraFI, PalmaPV, AraujoAG, QueirozRH, CovasDT, ZagoMA, PanepucciRA. 2011. Mesenchymal stromal cells upregulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res, 7:66–74.
74.
SundinM, D'arcyP, JohanssonCC, BarrettAJ, LönniesH, SundbergB, NavaS, KiesslingR, MougiakakosD, Le BlancK. 2011. Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?J Immunother, 34:336–342.
75.
MurayamaT, KatadaT, UiM. 1983. Guanine nucleotide activation and inhibition of adenylate cyclase as modified by islet-activating protein, pertussis toxin, in mouse 3T3 fibroblasts. Arch Biochem Biophys, 221:381–390.
76.
EvansBA, ElfordC, PexaA, FrancisK, HughesAC, DeussenA, HamJ. 2006. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res, 21:228–236.
77.
CarrollSH, WignerNA, KulkarniN, Johnston-CoxH, GerstenfeldLC, RavidK. 2012. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem, 287:15718–15727.
78.
OrrissIR, BurnstockG, ArnettTR. 2010. Purinergic signalling and bone remodelling. Curr Opin Pharmacol, 10:322–330.
79.
VassauxG, GaillardD, MariB, AilhaudG, NegrelR. 1993. Differential expression of adenosine A1 and A2 receptors in preadipocytes and adipocytes. Biochem Biophys Res Commun, 193:1123–1130.
80.
BørglumJD, VassauxG, RichelsenB, GaillardD, DarimontC, AilhaudG, NegrelR. 1996. Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation. Mol Cell Endocrinol, 117:17–25.
81.
Omatsu-KanbeM, InoueK, FujiiY, YamamotoT, IsonoT, FujitaN, MatsuuraH. 2006. Effect of ATP on preadipocyte migration and adipocyte differentiation by activating P2Y receptors in 3T3-L1 cells. Biochem J, 393:171–180.
82.
KramperaM, PizzoloG, ApriliG, FranchiniM. 2006. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone, 39:678–683.
83.
ShapiroF. 2008. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater, 15:53–76.
TrabanelliS, OcadlíkováD, GulinelliS, CurtiA, SalvestriniV, de Paula VieiraR, IdzkoM, Di VirgilioF, FerrariD, LemoliRM. 2012. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol, 189:1303–1310.
86.
PellegattiP, RaffaghelloL, BianchiG, PiccardiF, PistoiaV, Di VirgilioF. 2008. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One, 3:e2599.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
